top of page

C4 Therapeutics, Inc. (CCCC)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of C4 Therapeutics, Inc. (“C4” or the “Company) (NASDAQ: CCCC). Investors who purchased C4 securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether C4 and certain of its officers and/or directors have violated federal securities laws.


On April 8, 2022, the Company issued a press release entitled “C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader”.  The press release disclosed, among other data, that of the “[f]our patients [who] received single agent CFT7455 at the starting dose of 50 μg per day”, “[t]wo of these patients  were dose reduced to 25 μg per day due to neutropenia, a known on-target toxicity associated with IKZF1/3 degraders” and that “[t]wo dose-limiting toxicities (DLTs) were observed at the 50 μg per day starting dose, both consistent with on-target activity[.]”  On this news, C4’s stock price fell $3.31 per share, or 29.24%, to close at $8.01 per share on April 11, 2022.


If you are aware of any facts relating to this investigation or purchased C4 shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

bottom of page